Mannkind Corp (MNKD) 8.13 $MNKD
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
GlobeNewswire - Tue Aug 05, 4:00PM CDT
MannKind Corporation (Nasdaq:MNKD) will release its 2014 second quarter financial results on Monday, August 11, 2014 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM (Eastern Time) on August 11, 2014.
MannKind Shares Up 11.2% Since SmarTrend's Buy Recommendation (MNKD)
Comtex SmarTrend(R) - Tue Aug 05, 10:00AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 11.20% as of today's recent price of $8.29.
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
'Mad Money' Lightning Round: No Fan of Peabody Energy
at The Street - Wed Jul 30, 5:00AM CDT
Cramer says buy more Williams Companies and take a long-term view on SandRidge.
Jim Cramer's 'Mad Money' Recap: Looking at the Dark Side
at The Street - Tue Jul 29, 7:05PM CDT
Cramer says there are many trends in the markets that appear to be losing traction.
MannKind Up 16.7% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Tue Jul 29, 9:29AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 16.70% as of today's recent price of $8.70.
MannKind Falls 2.50% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Jul 25, 4:36PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $8.36 to a high of $8.97. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $8.71 on volume of 17.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Most active Nasdaq-traded stocks
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MannKind Afrezza Partnership News Coming Within Weeks
at The Street - Fri Jul 25, 10:30AM CDT
MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.
Will FDA Labelling Be MannKind's Downfall?
Alexander Maxwell, The Motley Fool - Motley Fool - Thu Jul 24, 7:10AM CDT
MannKind Corporation investors were finally successful, after multiple attempts, at obtaining FDA approval for Afrezza. There have recently been many different articles about the potential for partnerships for MannKind. However, I believe that...
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
3 Longtime Losers About to See Green?
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Imagine running a business that loses money every year for more than a decade. Now, imagine those losses combined total into the hundreds of millions -- even billions -- of dollars. If you're Al Mann with MannKind , John Scarlett with Geron ,...
MannKind Up 29.2% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Mon Jul 21, 4:53PM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 29.18% as of today's recent price of $9.63.
Critical Alerts For MannKind, CVS Caremark, Express Scripts, Cheniere Energy, and HomeAway Released By InvestorsObserver
PR Newswire - Mon Jul 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, CVS, ESRX, LNG, and AWAY.
Top Swing Trade Ideas for Monday July 21: Cliffs Natural Resources, MannKind, PolyOne
at The Street - Mon Jul 21, 8:19AM CDT
Here are some technical guidelines that you may be able to profit from.
Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.
Fed Chair Yellen Says Small Biotech Stocks Over-Valued
at The Street - Tue Jul 15, 12:10PM CDT
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
GlobeNewswire - Tue Aug 05, 4:00PM CDT
MannKind Corporation (Nasdaq:MNKD) will release its 2014 second quarter financial results on Monday, August 11, 2014 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM (Eastern Time) on August 11, 2014.
MannKind Shares Up 11.2% Since SmarTrend's Buy Recommendation (MNKD)
Comtex SmarTrend(R) - Tue Aug 05, 10:00AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 11.20% as of today's recent price of $8.29.
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
PR Newswire - Fri Aug 01, 8:00AM CDT
On Thursday, July 31, 2014, the NASDAQ Composite ended at 4,369.77, down 2.09%, the Dow Jones Industrial Average finished the day 1.88% lower at 16,563.30, and the S&P 500 closed at 1,930.67, down 2.00%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.37, down 2.03%, and the index has declined 0.02% in the last one month. Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation(NASDAQ: GERN), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research on these five companies can be accessed at:
'Mad Money' Lightning Round: No Fan of Peabody Energy
at The Street - Wed Jul 30, 5:00AM CDT
Cramer says buy more Williams Companies and take a long-term view on SandRidge.
Jim Cramer's 'Mad Money' Recap: Looking at the Dark Side
at The Street - Tue Jul 29, 7:05PM CDT
Cramer says there are many trends in the markets that appear to be losing traction.
MannKind Up 16.7% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Tue Jul 29, 9:29AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 16.70% as of today's recent price of $8.70.
MannKind Falls 2.50% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Jul 25, 4:36PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $8.36 to a high of $8.97. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $8.71 on volume of 17.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Most active Nasdaq-traded stocks
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
MannKind Afrezza Partnership News Coming Within Weeks
at The Street - Fri Jul 25, 10:30AM CDT
MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.
Will FDA Labelling Be MannKind's Downfall?
Alexander Maxwell, The Motley Fool - Motley Fool - Thu Jul 24, 7:10AM CDT
MannKind Corporation investors were finally successful, after multiple attempts, at obtaining FDA approval for Afrezza. There have recently been many different articles about the potential for partnerships for MannKind. However, I believe that...
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
3 Longtime Losers About to See Green?
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Imagine running a business that loses money every year for more than a decade. Now, imagine those losses combined total into the hundreds of millions -- even billions -- of dollars. If you're Al Mann with MannKind , John Scarlett with Geron ,...
MannKind Up 29.2% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Mon Jul 21, 4:53PM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 29.18% as of today's recent price of $9.63.
Critical Alerts For MannKind, CVS Caremark, Express Scripts, Cheniere Energy, and HomeAway Released By InvestorsObserver
PR Newswire - Mon Jul 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, CVS, ESRX, LNG, and AWAY.
Top Swing Trade Ideas for Monday July 21: Cliffs Natural Resources, MannKind, PolyOne
at The Street - Mon Jul 21, 8:19AM CDT
Here are some technical guidelines that you may be able to profit from.
Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.
Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.
Fed Chair Yellen Says Small Biotech Stocks Over-Valued
at The Street - Tue Jul 15, 12:10PM CDT
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.
